Vectra Cardiovascular Risk incorporates a personalized assessment of inflammation to predict a rheumatoid arthritis (RA) patient’s risk for a cardiovascular event in the next 3 years.
Vectra Cardiovascular Risk provides an actionable result at point of care that highlights the role of reducing systemic inflammation associated with RA.
Patients with RA have approximately 50% greater risk for cardiovascular disease compared to the general population.1
30% of cardiovascular risk in patients with RA is attributed to systemic inflammation and other RA related factors.2
Traditional cardiovascular (CV) risk factors do not fully explain the increased CV risk seen in RA patients.3
Cardiovascular disease (CVD) is the leading cause of mortality for patients with rheumatoid arthritis (RA), accounting for 30 – 40% of deaths. Patients with RA have approximately 50% greater risk for CVD compared to the general population. Accurate CVD risk prediction could improve care for RA patients. The MBDA-based CVD risk prediction score (Vectra Cardiovascular Risk) provides rheumatologists with a tool for assessing CVD risk to inform the management of traditional CVD risk factors and RA inflammation.3
Vectra Cardiovascular Risk was validated in a cohort younger than, and independent of, the Medicare cohort originally used for test development.
The Vectra Cardiovascular Risk score predicts risk for myocardial infarction (MI), stroke, or fatal CVD in the next three years for rheumatoid arthritis patients and has been internally validated. Goodness of fit analyses indicated good accuracy overall, and in subgroups based on level of Vectra Score, sex, and statin use.
High Vectra Scores are associated with an increased risk of hospitalized infection, myocardial infarction (MI) and coronary heart disease (CHD).
The Vectra Report gives a molecular assessment of RA disease. Vectra demonstrates its unsurpassed ability to predict radiographic progression as a personalized inflammatory measure for patients with RA. Vectra is a validated, advanced blood test performed by a CLIA-certified laboratory.
See sample report (coming soon)
Download the brochure to learn more about Vectra and how it can help to improve patient and provider decisions.